SEC Form 4 · accession 0001209191-17-002680
CONCERT PHARMACEUTICALS, INC. · CNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
D. Ryan Daws
Officer — Chief Financial Officer
Period of report
Jan 4, 2017
Accepted (ET)
Jan 6, 2017 · 5:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367920
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $10.97 | Jan 4, 2017 | A | 82,500 | A | — | Jan 3, 2027 | Common Stock | 82,500 | 82,500 | D |
Explanation of responses
- F1This option vests in sixteen equal quarterly installments beginning on April 4, 2017.